Back to search

National and Kapodistrian University of Athens

Γονιδιακό /πρωτεϊνικό προφίλ και υποκείμενοι μηχανισμοί της αυτοφαγίας στις αιματολογικές κακοήθειες

Abstract

dc:description

Myelodysplastic neoplasms (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of one or more hematopoietic lineages, peripheral blood cytopenias, and an increased risk of progression to acute myeloid leukemia. The most widely used prognostic classification system is the Revised International Prognostic Scoring System (IPSS-R), according to which patients are classified into five risk categories: very low, low, intermediate, high, and very high risk. The pathogenesis of MDS is multifactorial and involves genetic, epigenetic, and microenvironmental abnormalities affecting key pathways involved in cellular homeostasis. Despite significant advances in understanding the biology of MDS, the precise molecular mechanisms contributing to disease initiation, progression, and response to therapy remain largely unknown. Autophagy and apoptosis are two fundamental cellular processes that play crucial roles in regulating cell survival, the removal of damaged organelles and proteins, and programmed cell death. Autophagy functions as a recycling mechanism for cellular components and as an adaptive response to cellular stress, whereas apoptosis represents the primary mechanism for eliminating abnormal or dysfunctional cells. Dysregulation of the balance between these two processes has been associated with the development and progression of several neoplastic diseases, including MDS. However, their exact role in the pathophysiology of MDS, particularly in distinguishing low-risk from high-risk disease, has not yet been fully elucidated. This dissertation aimed to investigate the molecular mechanisms of autophagy and apoptosis in MDS at both the gene and protein expression levels, as well as to evaluate the effects of azacitidine, a hypomethylating agent widely used in the treatment of MDS, on these mechanisms. To achieve this objective, a combined experimental approach was employed, including the analysis of samples from patients with different prognostic categories of MDS, as well as an in vitro study using the MDS cell line (MDS-L).The study population consisted of 34 patients, including 13 low-risk and 21 high-risk MDS patients, as well as 23 healthy donors. None of the patients had received prior treatment. Patients were classified according to the Revised International Prognostic Scoring System (IPSS-R) into two major categories: low-risk (LR) and high-risk (HR). The LR group included patients with very low, low, and intermediate risk (IPSS-R ≤ 4.5), whereas the HR group included patients with high and very high risk (IPSS-R > 4.5). Bone marrow samples were collected from all patients, while peripheral blood samples were obtained from healthy donors. Leukocytes, RNA, DNA, and proteins were isolated from all samples. In the first stage, expression patterns of autophagy-related genes were investigated using RT² Profiler PCR Array technology. A total of 84 genes involved in different stages of the autophagic process were analyzed, including genes associated with autophagy initiation, autophagosome formation, cargo transport, and lysosomal fusion. The analysis demonstrated that 39 out of the 84 genes exhibited significantly reduced expression in MDS patients compared with healthy donors. These included key autophagy-related genes such as UVRAG, AMBRA1, PI3KC3, ATG5, ATG12, ATG16L1, DRAM1, DRAM2, and MAP1LC3B. In contrast, TGM2 was the only gene found to be significantly overexpressed in MDS patients.12 Genes exhibiting significant expression differences were selected for further validation by quantitative real-time PCR (qRT-PCR) in a larger number of samples. The qRT-PCR results confirmed the significant downregulation of PI3KC3, UVRAG, ATG5, ATG16L1, DRAM1, and MAP1LC3B expression in MDS patients, whereas TGM2 expression was significantly increased. Although no statistically significant differences were observed between low-risk and high-risk patients, HR patients consistently exhibited lower expression levels of most autophagy-related genes, suggesting a possible association between autophagy dysregulation and disease progression. Protein expression analysis by Western blot further confirmed these findings at the protein level. Specifically, PI3K, AMBRA1, UVRAG, ATG5, ATG12, ATG16, LC3B, and DRAM1 proteins showed significantly reduced expression in MDS patients compared with healthy donors, whereas TGM2 protein expression was increased. Furthermore, HR patients exhibited lower expression levels of autophagy-related proteins compared with LR patients, supporting the hypothesis that progressive suppression of autophagic activity is associated with a more aggressive biological behavior of the disease. In the second part of the study, the MDS-L cell line was used as an in vitro MDS model to investigate the effects of azacitidine on autophagy and apoptosis mechanisms. Initially, cell viability was assessed using the trypan blue exclusion assay in order to determine the appropriate drug concentration. Based on the results, a concentration of 0.5 μM azacitidine for 48 hours was selected, as it induced limited cytotoxicity (IC10), allowing the investigation of molecular alterations without extensive cell death.Gene expression analysis following exposure of cells to azacitidine revealed significant upregulation of genes associated with autophagy and apoptosis. Specifically, increased expression of the BECN1, ATG5, DRAM1, and MAP1LC3B genes was observed, suggesting activation of autophagic flux. Simultaneously, a significant increase in the expression of the apoptotic genes CASP3, CASP7, and CASP8 was detected, whereas the anti-apoptotic gene BCL-2 showed significantly decreased expression. These findings indicate that azacitidine simultaneously activates both autophagic and apoptotic pathways in MDS cells. Investigation of signaling pathways through phosphorylation analysis of 21 proteins using multiplex ELISA demonstrated significant alterations in pathways associated with cell survival and proliferation. Specifically, azacitidine suppressed the AKT/mTOR, NF-κB, and STAT3 pathways, which are associated with cell survival, while simultaneously activating p53 and ERK1 proteins involved in apoptosis and the cellular stress response. These findings were further confirmed at the protein level by Western blot analysis, where increased expression of BECN1, ATG5, and LC3II proteins, along with reduced BCL-2 expression, was observed. Overall, the findings of the present dissertation demonstrate that autophagy and apoptosis pathways are significantly dysregulated in MDS and that this dysregulation may contribute to disease pathogenesis and progression. Furthermore, the study highlights that azacitidine significantly affects the molecular pathways regulating autophagy and apoptosis, partially restoring the balance between these processes. These findings contribute to a more comprehensive understanding of the molecular biology of MDS and identify potential biomarkers and therapeutic targets that may support the development of more personalized and effective therapeutic strategies.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tsekoura, Georgia
  • Τσεκούρα, Γεωργία

Subjects

dc:subject × 23

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/62560

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tsekoura, Georgia; Τσεκούρα, Γεωργία. Γονιδιακό /πρωτεϊνικό προφίλ και υποκείμενοι μηχανισμοί της αυτοφαγίας στις αιματολογικές κακοήθειες. National and Kapodistrian University of Athens, 2026. http://hdl.handle.net/10442/hedi/62560